---
title: "SINOTHERAPEUTICS: Sales in the U.S. market have not been significantly affected, actively expanding into international markets"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239810612.md"
description: "SINOTHERAPEUTICS stated on the interactive platform that despite the uncertainty of bilateral tariff adjustments in the U.S. market, its sales in the U.S. market have not been significantly affected as of the first quarter of 2025. At the same time, the company is actively expanding into international markets and has reached cooperation agreements with distributors in several countries, with some products already approved for market launch, which is expected to have a positive impact on performance"
datetime: "2025-05-12T10:07:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239810612.md)
  - [en](https://longbridge.com/en/news/239810612.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239810612.md)
generator: "portal-rs"
---

# SINOTHERAPEUTICS: Sales in the U.S. market have not been significantly affected, actively expanding into international markets

On May 12th, SINOTHERAPEUTICS stated on the interactive platform that since the beginning of this year, the U.S. market has faced uncertainties due to bilateral tariff adjustments, which may adversely affect the company's product sales in the U.S. market. However, as of the first quarter of 2025, there have been no significant shelf adjustments in the company's sales in the U.S. market; at the same time, the company has actively expanded into other international markets in recent years, and has reached product cooperation agreements with relevant distributors in countries or regions such as Canada, Australia, Israel, Southeast Asia, Gulf countries, and Central and South America, with some products already approved for sale in the respective markets, which will have a positive impact on the company's performance

### Related Stocks

- [688247.CN](https://longbridge.com/en/quote/688247.CN.md)

## Related News & Research

- [Fosun Pharma subsidiary Shanghai Fosun Pharmaceutical Industrial Development wins China approval for new Luvometinib use in adult NF1 tumors](https://longbridge.com/en/news/297890174.md)
- [China Resources Pharma unit KPC wins registration to issue RMB 1 billion in medium-term notes](https://longbridge.com/en/news/297630970.md)
- [Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule](https://longbridge.com/en/news/297892535.md)
- [Haier-owned GE Appliances invests $1 billion to expand Louisville manufacturing hub](https://longbridge.com/en/news/297792498.md)
- [Biocytogen licenses fully human VHH antibody to Qilu Pharma in non-exclusive deal](https://longbridge.com/en/news/297781804.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**